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 The mechanistic target of rapamycin complex 1 (mTORC1) is a serine/threonine 
kinase that drives several anabolic processes including lipid synthesis, protein synthesis, 
and adipogenesis. mTORC1 is highly active in the livers of obese rodents, in 
overnutrition, and is implicated in the development of obesity related metabolic 
disorders, including the overproduction of atherogenic lipoproteins. Direct inhibition of 
mTORC1 is not a viable treatment strategy because it prevents feedback inhibition of the 
insulin-signaling cascade, leading to increased lipid synthesis and secretion of 
lipoproteins. Thus, therapeutic approaches that drive catabolic pathways are considered 
promising mechanisms for overcoming mTORC1-driven anabolism. Human liver HepG2 
cells were stably transduced with lentiviral shRNA targeting tuberous sclerosis complex 
2 (TSC2, upstream inhibitor of mTORC1) to constitutively activate mTORC1 or 
lentiviral scramble shRNA as negative control. In TSC2 shRNA cells, TSC2 gene and 
protein expression were suppressed, and mTORC1 activity (phospho-p70 S6K/p70 S6K) 
was subsequently increased. Hyperactive mTORC1 upregulated lipogenic and lipid 
transport genes and significantly increased cellular triacylglycerol content when 
  
compared to scramble shRNA cells. Furthermore, the constitutive activation of mTORC1 
increased apolipoprotein B (apoB) and triacylglycerol secretion into culture media. To 
determine if dietary agents would reverse mTORC1-mediated secretion of lipoproteins 
and triacylglycerides, TSC2 cells were treated with one of two short chain fatty acids, 
alpha-lipoic acid (LA; 200 µM) or 4-phenylbutyric acid (PBA; 8 mM).  LA and PBA 
significantly decreased secreted apoB and triacylglyceride despite their differential 
effects on mTORC1 activity; LA repressed mTORC1 signaling in TSC2 shRNA cells; 
whereas PBA did not. In addition to lowering secreted triacylglycerol LA decreased 
cellular triacylglycerol content but not PBA, which increased cellular triacylglycerol. We 
conclude that LA and PBA have the potential to lower the secretion of atherogenic 
lipoproteins associated with mTORC1 signaling hyperactivation. 
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CHAPTER 1 
LITERATURE REVIEW 
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Hypertriglyceridemia 
 
 Hypertriglyceridemia is a serious public health concern. Over 24% of the U.S.’ 
population has hypertriglyceridemia, with a higher prevalence (42.8%) among people 
aged ≥50 years [1]. The prevalence of hypertriglyceridemia in the U.S. has slowly 
declined from 33.5% in 1999 to 24.3% in 2010; however, this trend is likely attributable 
to the increased use of lipid-lowering agents from 8% to 15.6% in 1999 and 2010, 
respectively [2]. Hypertriglyceridemia, defined as abnormally high fasting serum 
triacylglycerides (TG) levels (>150 mg/dL or 1.8 mM), often occurs in people who are 
overweight or obese, and those with type 2 diabetes [1]. Elevated TG is considered to be 
a significant risk factor for cardiovascular disease. For example, each 1 mM (89 mg/dL) 
increase in TG translated to a 12% and 37% increase in cardiovascular disease risk in 
men and women, respectively [3]. Hypertriglyceridemia is also a significant risk factor 
for pancreatitis, liver disease, type 2 diabetes, and metabolic syndrome [4].   
 The first-line therapies for treating hypertriglyceridemia are lifestyle changes such 
as dietary modification, exercise, and weight loss. In extreme and persistent cases (≥200 
mg/dL or 2.26 mM), pharmacologic treatment options are utilized to lower TG including 
niacin, fish oil (omega-3 fatty acids), statins, fibrates, and thiazolidinediones (Table 1.1) 
[1]. The likelihood of controlling TG levels with lifestyle modifications at the population 
level is impractical, as obesity rates continue to climb despite countless public health 
initiatives [2]. At the individual level, drug therapies have demonstrated a notable ability 
to improve TG levels; however, negative side effects (e.g., flushing, gastrointestinal 
complaints, myopathy, worsening glycemia) remain a concern [1]. Thus, clinicians must 
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prescribe lipid-lowering drugs carefully, especially in patients with renal and hepatic 
impairments. This dilemma, along with the ongoing obesity and type 2 diabetes 
epidemics shed light on the importance of identifying safe and inexpensive therapeutic 
agents that would effectively reduce TG levels.   
Table 1.1. Select therapies for treating dyslipidemia. 
Therapy TG LDL-C HDL-C Potential adverse effects 
Fibrates 40-60% 5-30% 15-25% 
Myopathy, rhabdomyolysis, 
elevated liver enzymes 
Statins 20-40% 18-55% 5-15% 
Myopathy, rhabdomyolysis, 
elevated liver enzymes 
Niacin 30-50% 5-25% 20-30% 
Flushing, worsening glycemia,  
elevated liver enzymes 
Fish oils 30-50% 5-10% 5-10% 
Fishy aftertaste, gastrointestinal 
upset 
 
Lipid Transport and Metabolism  
 
 Free fatty acids (FFA) are energy dense molecules (9 kcal/g) that are utilized by 
select tissues for energy (e.g., muscle), and as a source of energy during periods of 
starvation. FFAs originate from dietary sources (exogenous), and through de novo 
lipogenesis (endogenous) in the liver in response to excess energy. Excess FFA are stored 
within adipose tissue as TG, which are formed through a condensation reaction between 
three FFA and a glycerol molecule. This reaction yields three molecules of water and one 
TG. The fatty acid composition of TG can be considerably diverse, differing in acyl chain 
length and degree of saturation. All TG are hydrophobic, have detergent-like properties, 
and are generally insoluble in blood, thus they require specialized transport structures 
called lipoproteins (Figure 1.1).  
4 
 
 
Figure 1.1. Generalized structure of a lipoprotein. Lipoproteins consist of a 
phospholipid monolayer with embedded proteins and free cholesterol. The neutral lipids 
(e.g., TG and cholesterol esters) that are nonpolar are found within the inner hydrophobic 
core of the lipoprotein. 
 
 Structurally, lipoproteins are comprised of a phospholipid monolayer shell that 
also contains free cholesterol and proteins. The phospholipids are positioned such that the 
polar head groups interact with aqueous environment of the blood, while the nonpolar 
acyl chains form a hydrophobic core that is compatible with the nonpolar nature of TG 
and cholesterol esters. This arrangement allows for the dispersion and transport of lipids 
within the aqueous environment of the blood. Lipoproteins also contain a variety of 
surface proteins known as apolipoproteins that serve as structural components, as well as 
cofactors and ligands for lipid metabolism.  
 Lipoproteins are classified according to their apolipoproteins, lipid composition, 
and density (lipid:protein ratio) (Table 1.2). There are four classes of lipoproteins that 
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include chylomicrons, very low-density lipoproteins (VLDL), low-density lipoproteins 
(LDL), and high-density lipoproteins (HDL). Chylomicrons are TG-rich lipoproteins that 
are synthesized and secreted by intestinal enterocytes after consumption of a lipid 
containing meal. The TG core is comprised of dietary lipid that had been hydrolyzed by 
digestive lipases (e.g., gastric lipase, pancreatic lipase) into FFA, transported inside of the 
cell, and then reassembled into TG. The resynthesized TG, cholesterol, phospholipids, 
and a truncated form of apolipoprotein B (apoB), apoB48, are assembled into 
chylomicrons and secreted into the lymphatic system. Chylomicrons enter systemic 
circulation through the thoracic duct, and subsequently deliver dietary TG to target 
tissues (e.g., adipose) via the action of lipoprotein lipase (LPL). LPL is expressed in 
adipose, muscle, mammary gland, brain, and luminal surface of capillaries and arteries. 
LPL catalyzes the hydrolysis of esterified fatty acids, yielding glycerol and free fatty 
acids that then enter the peripheral tissue for usage or storage. This reaction generates 
smaller, TG-poor chylomicron remnants that bind with hepatic lipoprotein receptor-
related protein 1 (LRP1) and apoB/E receptors to initiate receptor mediated endocytosis 
and clearance.  
Table 1.2. Defining features of the four classes of lipoproteins. 
Lipoprotein Chylomicrons VLDL LDL HDL 
Density (g/mL) < 0.95 0.95-1.006 1.019-1.063 1.063-1.225 
Diameter (Å) 1,000-10,000 300-800 200-250 50-120 
Defining 
Apolipoprotein 
apoB48 apoB100 apoB100 apoAI 
 
 The remaining classes of lipoproteins (VLDL, LDL, HDL) are responsible for 
transporting endogenous lipids, or those that arose from sources other than diet. TG-rich 
VLDL are synthesized and secreted from the liver and are characterized by the presence 
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of one full-length apoB100. In a process analogous to chylomicron metabolism, the TG 
within VLDL is catabolized into FFA and glycerol through the action of LPL. This 
reaction produces TG-poor IDL, then LDL through further processing. ApoB100 and 
ApoE found on the surface of LDL can then interact with hepatic LDL receptor (LDLR) 
to initiate clearance. Aberrant production and secretion of VLDL from the liver can lead 
to a host of conditions including hypertriglyceridemia, non-alcoholic fatty liver disease 
(NAFLD), cardiovascular disease, and type 2 diabetes. However, the molecular 
mechanisms involved in abnormal lipoprotein metabolism remain unclear.    
Assembly and Secretion of Very-Low Density Lipoprotein (VLDL)  
 
 VLDL particles are triacylglyceride-rich lipoproteins that are synthesized and 
secreted from the liver. VLDL transports TG that arise from de novo lipogenesis (fed 
state), and TG formed from FFA released from adipocytes (fasted state) to peripheral 
tissues including heart, adipose, and skeletal muscle. VLDL plays an essential role in 
lipid homeostasis; thus, its biogenesis is tightly controlled, primarily through regulation 
of apolipoprotein B (apoB) [5]. ApoB is an abundant protein that occurs in plasma as two 
distinct isoforms. The APOB gene is located on chromosome 2, and is expressed 
exclusively in the liver and small intestine. Though the entire gene is expressed in both 
tissues, mRNA editing in the intestine introduces a stop codon at residue 2153 resulting 
in a truncated version of apoB [6]. As a result of mRNA editing the apoB molecule is 
48% of full-length protein, designated apoB48, which is incorporated and secreted as the 
key identifier of chylomicrons [7]. Conversely, hepatocytes produce the full-length apoB 
protein that is referred to as apoB100 [7]. ApoB100 is a large protein that contains 4,536 
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amino acid residues and has a molecular weight of approximately 550 kDa [6]. Each 
VLDL contains a single, nontransferable apoB100 molecule that is subjected to a series 
of complex processing steps before it is secreted into circulation.  
 The amount of apoB secreted is primarily determined by the amount of protein 
that evades co- and post-translational degradation. For instance, in human hepatocellular 
carcinoma (HepG2) cells approximately 30-75% of newly synthesized apoB is degraded 
within a 2-3 hr period before the remaining protein is secreted [8–11]. ApoB mRNA is 
constitutively expressed and can be controlled by a process that involves the trafficking 
of apoB mRNA into P-bodies, aggregates of translationally repressed mRNAs [12,13]. 
ApoB mRNA that escapes this initial degradation is then translated, and subsequently 
lipidated by microsomal triacylglyceride transfer protein (MTTP) that prevents 
proteosomal degradation [14]. The addition of TG to nascent apoB by MTTP occurs 
during its contranslational translocation to the endoplasmic reticulum (ER) and gives rise 
to a dense, lipid-poor pre-VLDL particle [14]. Once inside of the ER lumen apoB can be 
regulated by ER60, a chaperone and protease that binds to and degrades overexpressed 
apoB [15]. Remaining apoB is then trafficked to the Golgi apparatus where it undergoes 
further lipidation in an MTTP-independent manner that involves apoCIII, an 
apolipoprotein secreted by the liver [16,17]. The TG that are used to lipidate apoB in the 
ER and Golgi are derived from FFA released from adipocytes, uptake of chylomicron and 
VLDL remnants, and de novo lipogenesis [5]. Secretion of the fully lipidated apoB 
particle can be inhibited by lysosomal and autophagic degradation [5]. Mature VLDL that 
escapes degradation and inhibitory mechanisms is then secreted from the hepatocyte 
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where it is either subjected to reuptake mediated by LDLR or enters circulation to deliver 
its cargo to peripheral tissues (Figure 1.2) [5].  
Figure 1.2. Molecular control mechanisms in the synthesis and secretion of very low-
density lipoprotein (VLDL). ApoB is lipidated with TG by MTTP in the ER to form a 
lipid-poor pre-VLDL particle. The pre-VLDL particle is then trafficked to the Golgi 
compartment where it is further lipidated in a MTTP independent manner that is 
promoted by apoCIII. ApoB is controlled by a variety of mechanisms, including 
proteasomal, autophagic, and lysosomal degradation. Green arrows indicate apoB-VLDL 
synthesis pathways; red dashed arrows indicate apoB degradation pathways. [Figure 
source: Haas et al., 2013] [5].   
 
Mechanistic Target of Rapamycin Complex 1 (mTORC1) 
 
 The mechanistic target of rapamycin (mTOR) is an evolutionarily conserved 
threonine/serine kinase that exists within two distinct protein complexes, mechanistic 
target of rapamycin complex 1 (mTORC1) and 2 (mTORC2). mTORC1 is comprised of 
five protein components: mechanistic target of rapamycin (mTOR), the catalytic subunit 
of the complex; regulatory-associated protein of mTOR (Raptor); mammalian lethal with 
Sec13 protein 8 (mLST8); proline-rich Akt substrate 40 kDa (PRAS40); and DEP-
domain-containing mTOR-interacting protein (Deptor) [18]. Raptor is essential for the 
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assembly of mTORC1, and recruitment and binding of mTOR substrates (p70 S6K1 and 
4E-BP1) [19,20]. mLST8 helps stabilize the mTOR-Raptor association by binding to 
interacting with the kinase domain of mTOR and plays a positive role in mTOR 
activation [21]. Conversely, PRAS40 and Deptor interact with and inhibit mTORC1 
activity and are degraded upon mTORC1 activation [18,22].  
Figure 1.3. Induction of mTORC1 signaling leads to activation of anabolic 
metabolism. Inactivation of the TSC1/2 complex allows GTP-bound Rheb to bind and 
activate mTORC1 kinase activity. mTORC1 phosphorylates p70 S6K which 
phosphorylates S6 and activates SREBP1; conversely, mTORC1inhibits the action of 4E-
BP1, ATG13 (autophagy-related protein 13), and ULK1/2 (UNC-51 like autophagy 
activating kinase) through phosphorylation. These reactions drive the anabolic processes 
of lipid synthesis and protein synthesis, while inhibiting the catabolic process of 
autophagy.  
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 mTORC1 senses and integrates many intracellular and extracellular signals 
including, nutrients (e.g., amino acids, glucose), hormones (e.g., insulin), growth factors, 
oxygen, ATP levels, and cytokines [23]. These signals potentiate a cascade that involves 
inhibition of the GTPase-activating protein (GAP) complex comprised of TSC1 
(hamartin) and TSC2 (tuberin) (TSC1/2) [23–25]. When the TSC1/2 complex is 
inhibited, it allows the activation of the small Ras-related small G protein Rheb (Ras 
homolog enriched in brain) via GTP-loading [26]. The GTP-bound Rheb acts as up-
stream activator of mTORC1, and is required for mTORC1 activity [22,23]. In instances 
of nutrient or energy depletion, the TSC1/2 complex hydrolyzes GTP-Rheb (active) to 
GDP-Rheb (inactive), thus preventing the activation of mTORC1 [24–26].  Upon 
activation, mTORC1 directly phosphorylates p70 S6 Kinase 1 (p70 S6K1) and eukaryotic 
translation initiation factor 4E binding protein 1 (4E-BP1) [27]. Phosphorylation of 
mTORC1’s downstream effectors potentiates the induction of anabolic cell growth (e.g., 
biosynthesis of proteins, lipids, organelles) and inhibition of catabolic processes (e.g., 
autophagy, ketogenesis) (Figure 1.3) [26,27].  
The role of mTORC1 in lipogenesis 
 
 mTORC1 is often regarded as a master regulator of cellular growth and 
metabolism through its induction of protein synthesis, lipogenesis, adipogenesis, and 
organelle biogenesis. mTORC1 has emerged as a critical regulator of lipid homeostasis in 
physiological and pathological states [26]. In a postprandial state mTORC1 is transiently 
activated by insulin and nutrient sufficiency in metabolically active tissues (e.g., liver, 
adipose, muscle) promoting lipogenesis and blocking β-oxidation. In a normal 
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physiological state, insulin binds with its tyrosine kinase receptor induces 
autophosphorylation of the receptor, and recruitment and phosphorylation of insulin 
receptor substrates 1 and 2 (IRS1 and IRS2) at multiple tyrosine residues [28]. The 
activated IRS then complex with PI3K and promotes the production of 
phosphatidylinositol (3,4, 5)-triphosphate that increases the recruitment and activation of 
protein kinase B (Akt) [26]. Akt phosphorylates and inactivates TSC2 and PRAS40 
allowing mTORC1 to become active and phosphorylate p70 S6K, which in turn 
phosphorylates several targets including ribosomal protein S6 and IRS1 (Figure 1.4) [26]. 
p70 S6K is required for mTORC1-mediated lipogenesis and is purported to play a role in 
the processing of sterol regulatory element-binding proteins (SREBP) in hepatocytes 
[29].  
Figure 1.4. Activation of mTORC1 through insulin signaling.  Insulin binds to its 
tryrosine kinase receptor and induces the recruitment of IRS1 and PI3-K leading to the 
activation of Akt. PRAS40 is inhibited by Akt, allowing mTORC1 to become active and 
phosphorylate its downstream effectors. p-p70 S6K inhibits IRS1 via a negative feedback 
loop, thus suppressing insulin signaling. [Figure adapted from: Chong and Maise, 2012] 
[30]. 
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Figure 1.5. Proposed activation mechanism of SREBP through insulin and 
mTORC1 signaling. Red and black arrows indicate inhibitory and stimulatory actions, 
respectively. The question marks indicate unknowns associated with the mechanism. 
[Figure adapted from: Jeon and Osborne, 2012] [31].  
 
SREBP-1 is a helix-loop-helix transcription factor that induces the expression of 
genes involved in cholesterol, fatty acid, triacylglyceride, and phospholipid synthesis 
[26]. SREBP-1 is synthesized in the ER as a precursor protein (125 kDa) that is bound to 
sterol-sensing binding partner (SCAP) and is retained in the ER by INSIG proteins 
(Figure 1.5) [26]. Upon sterol depletion, the SREBP1-SCAP is released from Insig2a and 
transported to the Golgi apparatus where they undergo proteolytic cleavage into a mature 
SREBP-1c (68 kDa) [26]. The mature SREBP-1c can then translocate into the nucleus, 
bind to the sterol response element (SRE), and induce transcription of lipogenic genes 
(e.g., acetyl-CoA carboxylase (ACC), fatty acid synthase (FASN), stearoyl-CoA 
desaturase 1 (SCD-1)) [26,32–34]. In primary rodent hepatocytes and intact liver, insulin 
or feeding increases SREBP-1c and its targets and promotes de novo lipogenesis in a 
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manner that is sensitive to the mTORC1-specific inhibitor rapamycin [32,35,36]. 
Additionally, expression of constitutively active Akt or loss of either TSC1 or TSC2 
results in insulin-independent activation of mTORC1 signaling, expression of SREBP-1c 
targets, and lipogenesis [29,37]. 
 The activation of lipogenesis is dependent on insulin signaling [26]; however, 
obese rodents with severe hepatic insulin resistance have hyperactive mTORC1 and 
lipogenic activity, suggesting that insulin resistance does not affect the mTORC1 
signaling cascade [26,38]. This hyperactivation of mTORC1 by overnutrition may 
promote lipogenesis by inducing SREBP-1c processing and explain why hepatic SREBP-
1c remains active during liver insulin resistance [26]. Although mTORC1 activation in 
vivo is essential, it is not sufficient to stimulate hepatic SREBP-1c and targets in response 
to feeding [35,39]. For instance, mice with liver-specific Raptor knockout (constitutive 
mTORC1 inhibition) fail to induce SREBP-1c and lipogenesis [39,40]; however, mice 
with liver-specific TSC1 knockout (constitutive mTORC1 activation) revealed that 
mTORC1 is not capable of activating SREBP-1c and hepatic lipogenesis on its own [35]. 
This paradoxical scenario is likely a result of a strong negative feedback mechanism in 
chronic mTORC1 activation that attenuates Akt signaling. Consistent with this idea, 
restoration of Akt activity in liver-specific TSC1 knockout mice leads to SREBP-1c 
activation and lipogenesis [35].  
The role of mTORC1 in lipid transport 
 
 There is mounting evidence suggesting that mTORC1 signaling is involved in 
lipid mobilization and transport. Conditions of overnutrition and obesity can lead to 
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chronically elevated mTORC1 signaling in liver and adipose, further contributing to the 
development of hypertriglyceridemia [41–43]. Evidence suggests that this phenomenon is 
a result of hyperglycemia and hyperinsulinemia associated with obesity [5]. In type 2 
diabetes and insulin resistance, mTORC1 remains active likely due to persistent 
hyperinsulinemia leading to increased de novo lipogenesis [42]. Concomitantly, insulin 
resistance in adipose promotes slow, yet constant increase in lipolysis that causes an 
increase in FFA that are delivered to the liver [5]. The FFAs are then incorporated into 
TG and used to lipidate apoB100, allowing the apoB protein to evade degradation and be 
secreted from the liver as VLDL. Recent reports have also suggested that ER stress, 
potentiated through chronic mTORC1 activation, may play a role in the secretion of apoB 
from hepatocytes [44,45]. The ER is a dynamic organelle that plays an important role in 
protein and lipid metabolism. When the ER is under stress (e.g, accumulation of 
misfolded or unfolded proteins), the unfolded protein response (UPR) is initiated through 
three proteins: inositol-requiring enzyme 1, activating transcription factor-6 (ATF6), and 
protein kinase-like ER kinase (PERK) [45]. Activation of the UPR leads to translation 
arrest, degradation of misfolded proteins, expression of ER chaperones, and ER 
membrane expansion to increase the protein-folding capacity. Overnutrition appears to 
induce the ER stress response, activate SREBP-1, and increase intracellular lipid levels in 
an mTORC1-dependent manner [45]. Induction of ER stress and mTORC1 activity has 
also been shown to suppress sortilin-1, a protein that may be involved in post-Golgi 
regulation of apoB by trafficking the protein towards degradation pathways [44]. The 
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molecular mechanisms involved in mTORC1 regulation of ER stress, apolipoprotein 
expression, and metabolism remains to be elucidated. 
 The central role of mTORC1 in regulating lipid homeostasis and its persistent 
activation in obesity and type 2 diabetes suggests mTORC1 inhibitors would offer 
therapeutic benefits in metabolic diseases.  However, patients treated with mTORC1 
inhibitors experience increased insulin resistance, hypertriglyceridemia, 
hypercholesterolemia, and elevated plasma FFA [46]. Accordingly, plasma levels of both 
apoB100 and apoCIII were increased in rapamycin-treated patients [47], and rapamycin-
treated guinea pigs experienced elevated circulating VLDL [48]. This phenomenon is 
thought to arise from a loss of the negative feedback on insulin signaling, allowing Akt to 
remain active and promote lipogenesis through SREBP-1c by suppressing Insig2a 
[35,49]. The negative side effects associated with direct inhibition of mTORC1 provide 
support for the identification of potential bioactive and therapeutic compounds capable of 
activating catabolism.   
(R)-α-Lipoic acid  
 
 (R)-α-Lipoic acid (LA), also known as 1,2-dithiolane-3-pentanoic acid or thioctic 
acid, is a naturally occurring dithiol compound that is synthesized enzymatically from 
octanoic acid in most prokaryotic and eukaryotic microorganisms as well as in plant and 
animal mitochondria [50]. In the mitochondrion, LA serves as an essential cofactor for 
the lipoamide containing enzyme of aerobic metabolism [51]. Though de novo synthesis 
provides all the LA necessary for its function in the mitochondria, LA can also be 
absorbed from dietary sources such as muscle and organ meats (e.g., heart, liver), and to a 
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lesser degree dark green, leafy vegetables (e.g., spinach). In food, LA is present in a 
lipollysine form and ranges from 0.55 to 2.36 μg/g dry weight in meats [52] and 0.16 to 
3.15 μg/g dry weight in vegetables [53]; however, a typical adult consuming a Western 
type diet, no LA can be detected in circulation [54]. Conversely, commercially available 
LA dietary supplements (ranging from 50 to 600 mg) are able to markedly increase 
plasma concentrations of LA to 1-225 μM, and are generally responsible for the positive 
health outcomes reported in the literature derived from LA supplements [54–58]. 
 Growing evidence suggests that orally supplied LA promotes several biochemical 
activities with potential therapeutic value against a host of pathophysiological conditions, 
including diabetic polyneuropathies, inflammation, hepatic diseases [51]. LA has also 
been described as a potent biological antioxidant and a detoxification agent that is 
capable of scavenging a variety of reactive oxygen species, chelating transition metals, 
regenerating vitamins C and E, and increasing intracellular ubiquinone and reduced 
glutathione levels [51]. This array of cellular and molecular functions has stimulated 
considerable interest among the lay public and the research community for the use of LA 
both as a nutraceutical and as a pharmacotherapy. Recently, the TG-lowering properties 
of dietary LA have been recognized both in laboratory animals [59,60] and humans  
[61,62]. Despite these reports, the molecular mechanisms by which LA regulates blood 
TG remain ill defined. 
4-Phenylbutyric acid 
 
 4-Phenylbutyric acid (PBA) is an aromatic short chain fatty acid (SCFA) and 
chemical chaperone commonly used to alleviate ER stress and facilitate proteostasis [63]. 
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PBA is a chemical derivative of butyric acid, a SCFA produced via microbial 
fermentation in the gut. Like butyric acid, PBA has demonstrated considerable ability to 
regulate gene expression by inhibiting histone deacetylase activity (HDAC) [63]. 
Currently, sodium PBA was approved in 2013 by the US Food and Drug Administration 
for use as an ammonia scavenger in patients with urea cycle disorders [64].  
 There are an increasing number of studies that suggest that PBA, acting as a 
chaperone or HDAC inhibitor, can impart beneficial effects on several pathologies 
including cancer, metabolic syndrome, diabetes, and urea cycle disorders. There is also 
mounting evidence that PBA has anti-obesity and lipid-lowering properties [44,65–67]. 
For instance, PBA supplementation induced the expression of peroxisome proliferator-
activated receptor alpha (PPARα) and genes involved in peroxisomal β-oxidation in 
livers of mice [65], while reducing lipogenic protein (e.g., ACC, FAS, SREBP-1, SCD-1) 
levels in livers of rats [66]. PBA also reduced plasma triacylglycerols in mice [65], 
hepatic steatosis, and body weights in rats [66,67].  
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mTORC1 CONSTITUTIVE INHIBITION AND 
ACTIVATION: A MODEL AND ITS 
CHARACTERIZATION 
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INTRODUCTION 
 
 Hypertriglyceridemia is a serious public health issue that affects over 24% of 
Americans [1]. Defined as abnormally high fasting plasma triacylglycerols (TG; >150 
mg/dL or 1.8 mM), hypertriglyceridemia is a comorbidity of obesity and type 2 diabetes 
and is a significant risk factor of cardiovascular disease [1,2]. Increased assembly and 
secretion of very low-density lipoproteins (VLDL) from the liver in obesity is thought to 
drive the development of hypertriglyceridemia. This process involves elevated lipidation 
of apolipoprotein-B100 (apoB; an essential protein of VLDL) from hepatic derived TG, 
which is then secreted into circulation. VLDL assembly and secretion pathways are well 
studied; however, the molecular mechanisms behind the pathogenesis of 
hypertriglyceridemia in obesity are ill defined.   
 The mechanistic target of rapamycin (mTORC1) is a critical regulator of anabolic 
metabolism and is highly active in the livers of obese rodents [3]. mTORC1 is a 
threonine/serine kinase that is structurally composed of mechanistic target of rapamycin 
(mTOR), regulatory-associated protein of mTOR (Raptor), and mammalian lethal with 
Sec13 protein 8 (mLST8), whereas inactive mTORC1 includes the aforementioned 
proteins plus DEP-domain-containing mTOR-interacting protein (Deptor) and proline-
rich Akt substrate 40 kDa (PRAS40) [4,5]. mTORC1 is controlled by the upstream 
GTPase-activating protein tuberous sclerosis complex (TSC) (TSC1/2) comprised of 
TSC1 (hamartin) and TSC2 (tuberin) [5–7]. TSC1/2 negatively regulates mTORC1 
activity by increasing the levels the GDP-bound Ras homolog enriched in brain (Rheb) 
[8]. Conversely, when TSC1/2 is inhibited, Rheb is GTP-bound and can bind to and 
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activate mTORC1 [8]. mTORC1 has emerged as a critical coordinator between 
nutritional status and cellular growth machinery. In overnutrition mTORC1 is 
constitutively active leading to increased activity of its downstream effectors, including 
p70 S6 kinase 1 (p70 S6K1) [5,8]. Activation of mTORC1 also induces the expression of 
hepatic SREBP-1c and lipogenesis [9,10]. Additionally, hyperinsulinemic obese mice 
experience hyperactive hepatic mTORC1 signaling and increased levels of circulating 
VLDL and TG [11–13]. The exact mechanism in which mTORC1 potentiates the 
development of hypertriglyceridemia are unknown. These observations led us to 
investigate the effects of constitutive activation or inhibition or mTORC1 activity in the 
secretion of apoB-containing lipoproteins and TG from hepatocytes.   
 
MATERIALS AND METHODS 
 
Cell Culture 
 
HepG2 cells were purchased from American Tissue Culture Collection 
(Manasssa, VA). Lenti-X 293T cells were purchased from Clontech Laboratories 
(Mountain View, CA). Huh7 cells were kindly provided by Dr. Qiaozhu Su (University 
of Nebraska-Lincoln, NE, USA). HepG2 cells were maintained in low glucose (5.5 mM) 
Dulbecco’s Modified Eagle’s Medium (#11885-076; Life Technologies) supplemented 
with 10% fetal bovine serum (FBS) (#30-2020; ATCC) and antibiotics/antimycotics 
(#A5955; Sigma). Lenti-X 293T cells were maintained in high glucose (25 mM) 
Dulbecco’s Modified Eagle’s Medium (#11995-040; Life Technologies) supplemented 
with 10% FBS and antibiotics/antimycotics. Huh7 cells were maintained in high glucose 
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(25 mM) Dulbecco’s Modified Eagle’s Medium (#11995-040; Life Technologies)  
supplemented with 10% FBS, antibiotics/antimycotics, and Hyclone MEM-nonessential 
amino acids (Thermo Scientific). All cells were maintained at 37oC in 5% CO2 with 
medium renewal ever 3-4 days. For experimental treatments, stably transduced HepG2 
cells were washed twice with PBS, serum-starved overnight (~16 hrs), and treated as 
indicated in corresponding figure legends in serum-free DMEM (5.5 mM or 30 mM 
glucose). 
 
Lentivirus-mediated Short Hairpin RNA Silencing 
 
pLKO.1 plasmids containing shRNA expression cassettes were purchased from 
Addgene (Cambridge, MA). The oligonucleotides encoding the short hairpin RNA 
(shRNA) transgene targeting Raptor (#1858; Addgene) [14] and TSC2 (#15478; 
Addgene) [15] have been previously described. A scramble (#1864; Addgene) [14] 
shRNA sequence was used as a negative control. Lentivirus were produced by 
transfecting Lenti-X 293T cells grown in 6-well dishes with 1 µg of the pLKO.1 plasmid 
containing the appropriate shRNA and Lenti-vpack packaging kit (#TR30022; OriGene) 
for 18 hours. Two batches of virus containing supernatants were collected at 48 and 72 
hours after transfection, combined, and concentrated using Lenti-X concentrator 
(#631231; Clontech). Viral titers were then calculated using Lenti-X qRT-PCR Titration 
Kit (#631235; Clontech). Target cells grown in 12-well dishes were infected using a 
multiplicity of infection of 10 in the presence of 8 µg/ml Polybrene (Sigma) for 24 hours 
then selected for with 2 µg/ml puromycin (Sigma) for 5 days. Cells were analyzed for 
knockdown efficiency 120 hours post-infection. Polyclonal stably transduced HepG2 and 
28 
 
Huh7 cells were generated by infecting cells with shRNA-containing lentivirus, and 
selection with puromycin (2 µg/ml) for 2 weeks.  
 
Cell lysis and Western blotting 
 
Cells were washed twice in ice-cold phosphate-buffered saline (PBS) and 
solubilized in modified RIPA buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 
1 mM EGTA, 1% Na deoxycholate, 1% Igepal, 1 mM DTT) supplemented with Halt 
protease and phosphatase inhibitors (Thermo Scientific). The cells were then scraped, 
vortexed for 1 minute, and then clarified by centrifugation for 10 min at 14,000 x g at 
4oC. Total protein concentration of clarified supernatants was determined using the Pierce 
BCA Assay (Thermo Scientific) and Bio-Tek µQuant plate reader. Samples were then 
adjusted to appropriate concentrations using ice-cold PBS and SDS loading buffer 
supplemented with 100 mM DTT, and denatured for 5 min at 95oC. Secreted proteins in 
conditioned media were prepared by adding Halt protease inhibitors (Thermo Scientific), 
vortexing, and centrifugation for 10 min at 14,000 x g at 4oC. The clarified media was 
then transferred to a fresh tube, vortexed briefly, and equal volumes denatured with SDS 
loading buffer supplemented with 100 mM DTT denatured for 5 min at 95oC, and 
subjected to Western blot analysis. Briefly, proteins were resolved by reducing SDS-
PAGE, transferred onto a nitrocellulose membrane (LI-COR), blocked for 1 hour at room 
temperature in Odyssey Blocking Buffer (LI-COR) in TBS, and probed overnight at 4oC 
with respective primary antibody. Antibodies against Raptor (#2280), TSC2 (#4308), p70 
S6K (#2708), phospho-p70 S6K (Thr389; #9234), and FASN (#3180) were purchased 
from Cell Signaling (Danvers, MA); ApoB (#71307) and ApoE (#71707) from Midland 
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Bioproducts (Boone, IA); β-Actin (#A5441) from Sigma-Aldrich (St. Louis, MO). IRDye 
secondary antibodies were purchased from LI-COR (Lincoln, NE). HRP-conjugated 
secondary antibodies against rabbit, mouse, and goat were purchased from R&D 
Systems, Cell Signaling, and Santa Cruz Biotechnology, respectively. Blots were 
visualized using either the LI-COR Odyssey scanner or enhanced chemiluminescence 
(ECL) on the ProteinSimple imaging system. All band densitometry quantification was 
completed with the LI-COR Image Studio Lite software.  
 
Measurement of intracellular and secreted TG content 
 
Lipids were extracted from stably transduced HepG2 cells and conditioned media 
(2 mL) using the chloroform/methanol method previously described with modifications 
[16]. TG were then quantified enzymatically using Triacylglycerol determination 
reagents (Sigma) and Bio-Tek µQuant plate reader. 
 
Quantitative Real-Time PCR (qRT-PCR) 
 
Total RNA was isolated from cells using BioRad Aurum Total RNA Mini Kit. 
First strand cDNA was synthesized from 1 µg total RNA with oligo (dT) and random 
primers using BioRad iScript reverse transcription supermix according to manufacturer’s 
instructions. All qRT-PCR were performed on a BioRad CFX96 Real-Time PCR 
Detection System using Sso Advanced SYBR Green supermix (BioRad). Amplicons 
were confirmed by melt curve analysis and agarose gel electrophoresis. PPIA was used as 
the internal reference gene to normalize expression levels of all targets. Primer sequences 
are given in Table 2.1. 
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Statistical Analysis 
 
Results are expressed as means ± SEM. Statistical significance was determined as 
denoted in figure legends using an unpaired two-tailed Student’s t test, One-Way 
ANOVA Tukey’s Multiple Comparisons Test, or Two-Way ANOVA with Bonferroni 
Post-Test. All statistical tests were performed at the 5% significance level.   
 
RESULTS 
 
Lentiviral-mediated shRNA transduction transiently decreased Raptor and TSC2 
expression in HepG2 and Huh7 cells.  
Table 2.1. Oligonucleotide primer sequences used for qRT-PCR. 
Gene Sequence (5’→3’)a 
Product 
Size (bp) 
GenBankb Ref. 
RPTOR 
TGGAGTCCGAAATGCTGCAA 
176 NM_001163034.1 
 
ACTGACTGTCTTCATCCGATCC 
TSC2 
GGCAAGAGAGTAGAGAGGGACG 
116 NM_000548.3 
[25] 
AAGAAGGGGGAATGGTAGAGC 
APOB 
CAGCTGATTGAGGTGTCCAG 
86 NM_001159323.1 
 
CACTGGAGGATGTGAGTGGA 
SREBF1 
CAGCCCCACTTCATCAAGG 
161 NM_004176.4 
[26] 
ACTGTTGCCAAGATGGTTCCG 
MTTP 
TGTGGCCTTACTATGGAGGAA 
184 NM_000253.2 
[27] 
AAGGAGCGTAGGTCTTTGCAG 
PPIA 
TTCATCTGCACTGCCAAGAC 
152 NM_001300981.1 
 
 TGTCCACAGTCAGCAATGGT 
FASN 
ACAGCGGGGAATGGGTACT 
188 NM_004104.4 
 
GACTGGTACAACGAGCGGAT  
DGAT1 
GTTATTGCGGCCAATGTCTT 
150 NM_012079.5 
 
AACCAGTAAGACCACAGCCG 
DGAT2 
CAGGTCATCTCAGTGCTCCA 
TCCAGTCAAACACCAGCCAA 
139 NM_032564.4 
 
a Shown as sense primer followed by antisense primer 
b GenBank accession number 
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 HepG2 and Huh7 were transiently infected using lentiviral-mediated gene 
delivery with an MOI of 10 to determine if the shRNAs targeting Raptor (shRaptor) and 
TSC2 (shTSC2) would effectively reduce the expression of the respective mRNAs and 
proteins. shRaptor significantly decreased mRNA levels by 78% and 61% in HepG2 and 
Huh7 cells, respectively when compared to shScramble control. Raptor protein levels 
were also markedly lower in both HepG2 and Huh7 cells (Fig. 2.1, A). shTSC2 
significantly decreased mRNA levels of TSC2 by 74% and 73%, respectively when 
compared to scramble controls, and equated to lower TSC2 protein in HepG2 and Huh7 
cells (Fig. 2.2, B).  
Fig. 2.1. Validation of lentiviral-mediated knockdown of TSC2 and Raptor at the 
mRNA and protein level in HepG2 and Huh7 cells. Raptor and TSC2 mRNA levels 
were normalized to the housekeeping gene PPIA; whereas, Raptor and TSC2 protein 
levels were normalized to β-Actin. Data represent mean ± SEM, n = 4. (A) The Raptor 
shRNA significantly reduced Raptor mRNA levels in both HepG2 and Huh7 cell lines by 
78% and 61%, respectively. Raptor protein levels were also reduced in both cell lines.  
(B) The TSC2 shRNA significantly reduced TSC2 mRNA levels in both HepG2 and 
Huh7 cell lines by 74% and 73%, respectively. TSC2 protein levels were also reduced in 
both cell lines. Statistical significance was determined using an unpaired Student’s t-test. 
*P < 0.05 versus scramble control.  
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Knockdown of Raptor and TSC2 was maintained in stably transduced HepG2 cells, 
and leads to modulation of mTORC1 activity  
 Stably transduced HepG2 cell lines containing shScramble, shRaptor, or shTSC2 
were created to increase reproducibility of downstream experiments and analyses. The 
shRaptor cells had a 69% and 90% knockdown of Raptor mRNA and protein levels, 
respectively (Fig. 2.2, A); whereas the shTSC2 cells had a 71% and 72% knockdown of 
TSC2 mRNA and protein levels, respectively (Fig. 2.2, B). Next, we examined the 
phosphorylation state of p70 S6K, an mTORC1 downstream effector, to determine if the 
suppression of Raptor and TSC2 affects mTORC1 activity. Knockdown of Raptor 
significantly decreased the kinase activity of mTORC1 as denoted by 29% lower 
phospho-p70 S6K (Fig. 2.2, A).  Conversely, knockdown of TSC2 significantly increased 
the phosphorylation of p70 S6K by 82% suggesting heightened mTORC1 kinase activity 
(Fig. 2.2, B).  
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Fig 2.2. Knockdown of Raptor and TSC2 is maintained in stably transduced HepG2 
cells, leading to modulation of mTORC1 activity. Raptor and TSC2 mRNA levels 
were normalized to housekeeping gene PPIA. Raptor and TSC2 protein were normalized 
to β-Actin, whereas phospho-p70 S6K was normalized to total p70 S6K. Data represent 
mean ± SEM, n = 4. (A) Raptor cells have a 69% decrease in Raptor mRNA levels, and a 
90% reduction of Raptor protein. The knockdown of Raptor lead to a 29% reduction in 
phosho-p70 S6K (Thr389). (B) TSC2 protein levels were reduced by 72% in stable TSC2 
cells. TSC2 cells have a 71% decrease in TSC2 mRNA levels. The knockdown of TSC2 
lead to an 82% increase in phosho-p70 S6K (Thr389). Statistical significance was 
determined using an unpaired Student’s t-test. *P < 0.05 versus scramble control. 
 
 
Serum withdrawal does not alter cellular morphology or differences in mTORC1 
activity  
 Fetal bovine serum (FBS), a common additive to cell culture mediums, contains a 
wide variety of growth factors needed for survival and propagation of mammalian cells. 
While FBS is essential to maintaining healthy cultures, it can contain a variety of factors 
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(e.g., fatty acids, cytokines) that can impact the outcome of cellular experiments. In order 
to control for this potential confounding factor, we conducted our experiments in medium 
devoid of FBS. Culturing stably transduced HepG2 cells in serum-free medium did not 
negatively impact cellular morphology (Fig. 2.3). Additionally, the percent knockdown of 
Raptor and TSC2 protein levels was not affected by serum withdrawal (Fig. 2.4), and the 
percent decrease in phosphorylation of p70 S6K in shRaptor cells was not significantly 
different between serum and serum-free conditions (Fig. 2.4). The phosphorylation of 
p70 S6K remained elevated in shTSC2 cells under both serum conditions, however, 
shTSC2 cells cultured without FBS for 48 hrs exhibited a 25% increase in p70 S6K 
phosphorylation when compared to the p-p70 S6K increase in FBS treated cells (Fig. 
2.4). 
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Fig. 2.3. Morphology of stably transduced HepG2 cells remains consistent during 
serum withdrawal. (A) Experimental timeline of serum withdrawal. (B) The 
morphology of stably transduced scramble, TSC2, and Raptor HepG2 cells remains 
consistent over a 48 hr serum withdrawal period.   
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Fig. 2.4. Serum withdrawal does not alter changes in knockdown or mTORC1 
activity. Cells were cultured in 5.5 mM glucose with or without FBS for 48 hrs, then 
harvested for total cellular proteins. Raptor and TSC2 protein levels were normalized to 
β-Actin, whereas p-p70 S6K was normalized to total p70 S6K. Data represent mean ± 
SEM, n = 4. (A) The removal of FBS from stably transduced shRaptor cells did not affect 
knockdown of Raptor (F = 0.01, P = 0.9395) or the phosphorylation of p70 S6K (F = 0.0, 
P = 0.9719). (B) Culturing shTSC2 cells did not affect knockdown of TSC2 (F = 0.0, P = 
1) or the phosphorylation of p70 S6K (F = 3.09, P = 0.1042). Statistical significance was 
determined using a two-way ANOVA, with Bonferroni Post-Test. 
 
 
Knockdown of TSC2 increases the expression of genes involved in lipogenesis and 
lipid transport 
 mTORC1 has emerged as a critical regulator in lipid homeostasis and its 
activation can induce de novo lipogenesis [17]. We examined the effects of genetic 
manipulation of mTORC1 activity on the expression of genes involved in lipid synthesis 
and mobilization. SREBP-1 (+51%) and fatty acid synthase (FASN; +55%) message 
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levels trended higher in shTSC2 cells, though the results did not reach significance (Fig. 
2.5, A). Transcript levels of diacylglycerol O-acyltransferase protein 1 (DGAT1) and 2 
(DGAT2) were significantly increased by 97% and 229% in shTSC2 cells, respectively 
when compared to shScramble (Fig. 2.5, A). The message levels of SREBP1, FASN, 
DGAT1, and DGAT2 were not significantly affected by suppression of Raptor. 
Considering hepatic derived lipids are synthesized for storage and export, we examined 
the levels of two genes essential for the export of hepatic TG: microsomal 
triacylglyceride transfer protein (MTP) and apolipoprotein B (apoB). Knockdown of 
TSC2 led to a 130% and 182% significant increase in MTP and apoB message levels, 
respectively (Fig. 2.5, A).  
 We did not observe significant differences in FASN protein levels, a target gene 
of SREBP-1, (Fig. 2.5, B) which is consistent with the non-significant changes in FASN 
mRNA levels. There were significant differences in the cellular TG content between the 
three cell lines. Suppression of TSC2 significantly increased TG (+26.8%), whereas 
knockdown of Raptor significantly decreased cellular TG (-42.9%).  
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Fig. 2.5. mTORC1 activation increases the expression of genes involved in 
lipogenesis and lipid transport, and cellular triacylglycerides. Cells were treated with 
30 mM glucose for 48 hrs and then harvested for total mRNA and protein. mRNA levels 
were normalized to the housekeeping gene PPIA. Protein levels were normalized to β-
Actin.  Data represent mean ± SEM, n = 3. (A) Gene expression of MTP (+130%), APOB 
(+220%), DGAT1 (+97%), and DGAT2 (+229%) were significantly higher in shTSC2 
cells while SREBP1 (+51%) and FASN (+55%) mRNA levels trended higher but did not 
reach significance. (B) FASN protein levels were not significantly different between the 
three stable lines. (C) The knockdown of TSC2 increased cellular TG content by 26.8%, 
while knockdown of Raptor decreased cellular TG by 42.9% when compared to 
shScramble (n = 4). Statistical significance was determined using a One-Way ANOVA 
with Tukey’s Multiple Comparisons Test. Means without a common letter differ, P < 
0.05.  
 
mTORC1 is involved in lipogenesis and secretion of apoB-containing lipoproteins 
and TG 
  Previous reports have suggested that mTORC1 hyperactivation increases VLDL 
and TG secretion in rodents [11–13]. apoB is required for VLDL assembly and secretion, 
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and is used as a marker of VLDL levels in circulation; thus we examined secreted apoB 
and apoE protein levels in the media of cells treated with 5.5 mM and 30 mM glucose to 
determine if mTORC1 activity impacts secretion of VLDL. shRaptor cells secreted 
significantly less apoB under 5.5 mM (-60.3%) and 30 mM (-71%) glucose conditions, 
and secreted less apoE (-61.3%) under 30 mM glucose (Fig. 2.6, A).  Hyperactivation of 
mTORC1 in shTSC2 cells promoted the secretion of significantly more apoB (+124.3%) 
under 30 mM glucose conditions. In euglycemic conditions (5.5 mM glucose), secreted 
apoB from shTSC2 was not significantly higher than the scramble control (Fig. 2.6, A). 
Secreted TG (Fig. 2.6, C) followed a similar trend to apoB, in that TG levels were lower 
(-39.7%) in the shRaptor cells and higher (+43.6%) in the shTSC2 cells.  
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Fig. 2.6. Chronic activation of mTORC1 increases secretion of apoB-containing 
lipoproteins and triacylglycerides under high glucose conditions. Data represent mean 
± SEM. (A) Activation of mTORC1 through TSC2 knockdown increased (+124.3%) 
secretion of apoB-containing lipoproteins under high glucose conditions; conversely, 
mTORC1 inhibition through Raptor knockdown decreased secretion of apoB-containing 
lipoproteins under low (-60.3%) and high (-71%) glucose conditions. Secreted apoE 
levels from TSC2 cells were not significantly different in either glucose condition; 
however, suppression of Raptor significantly reduced (-61.3%) apoE secretion under high 
glucose (n = 3). (B) The activation of mTORC1 through TSC2 knockdown increased 
secretion of TG by 43.6%, whereas knockdown of Raptor reduced the secretion of TG by 
39.7% when compared to Scramble control (n = 6). Statistical Significance was 
determined using a One-Way ANOVA, with Tukey’s Multiple Comparison Test. Means 
without a common letter differ, P < 0.05. 
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DMSO does not alter elevated secretion of apoB from shTSC2 cells or affect trends 
observed between shScramble, shRaptor, and shTSC2 cells 
 Dimethyl sulfoxide (DMSO) is an organosulfur compound commonly used as an 
organic solvent for polar and nonpolar compounds. DMSO will be used as a vehicle for 
bioactive compound delivery in future studies, thus it was important to determine if the 
DMSO would alter apoB secretion patterns observed in the stable cells. Secreted apoB 
and apoE levels from shTSC2 cells treated with 0.1% DMSO (24 hrs) did not change 
(Fig. 2.7, A).  Further, the changes in apoB and apoE secretion seen between the three 
stable cell lines were also observed in the presence of 0.1% DMSO (Fig. 2.7, B). 
Fig. 2.7. mTORC1-driven secretion of apoB remains elevated when treated with 
DMSO under high glucose. Data represent mean ± SEM. (A) shTSC2 cells were treated 
with 0.1% DMSO or water control for 24 hrs in 30 mM glucose medium. The addition of 
DMSO did not significantly impact (P > 0.05) the secretion of apoB-containing 
lipoproteins from shTSC2 cells (n = 4). Statistical Significance was determined using an 
unpaired Student’s t-test. (B) Stably transduced shScramble, shRaptor, and shTSC2 cells 
were treated with 0.1% DMSO in 30 mM glucose for 24 hrs. When compared to 
shScramble control shTSC2 cells secreted 60% more apoB-containing lipoproteins; 
conversely, shRaptor cells secreted 68% less apoB-containing lipoproteins (n = 3). 
Statistical Significance was determined using a One-Way ANOVA, with Tukey’s 
Multiple Comparison Test. Means without a common letter differ, P < 0.05.  
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DISCUSSION 
 
 Overnutrition is strongly associated with obesity and is thought to promote the 
development of hypertriglyceridemia. However, mechanisms by which nutrient excess 
promote the development of hypertriglyceridemia are not well defined. Recently, a 
master regulator of anabolic metabolism, mTORC1, was shown to be hyperactive in the 
livers of obese rodents and to be activated in states of nutrient and energy excess 
[18,3,19]. This observation led us to develop a liver cell model in which to manipulate 
mTORC1 activity and evaluate the effects of dietary bioactive compounds on mTORC1 
signaling and its consequences. Thus, this study was designed to accomplish two distinct 
aims: 1) create and characterize a model of mTORC1 hyperactivation and inhibition; and 
2) validate experimental conditions for future studies. 
 Many studies of human apoB metabolism have utilized the HepG2 cell line, 
however these cells secrete relatively dense, lipid poor lipoproteins that resemble LDL. 
This is due to the cell’s limited ability to fully lipidate apoB and secrete VLDL-sized 
particles [20]. An alternative human hepatoma cell line, Huh7, is being increasingly used 
to study apoB and VLDL metabolism [20–22]. Thus we validated the efficiency of 
shRNA-mediated knockdown of TSC2 and Raptor as models of mTORC1 
hyperactivation and chronic inhibition, respectively in both cell lines. Transient 
transduction of the cell lines effectively decreased the expression of Raptor and TSC2 
message and protein in HepG2 and Huh7 cells; however, the knockdown of each target 
was greater in HepG2 cells. The higher degree of gene silencing, along with the fact that 
Huh7 cells do not offer any advantage over HepG2 cells as a model of lipoprotein 
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metabolism [20] led us to create stably transduced HepG2 cell lines for shScramble, 
shRaptor, and shTSC2. The degree of target gene suppression remained high in stably 
transduced HepG2 cells, and resulted in significant modulations in mTORC1 kinase 
activity, as measured by phosphorylated p70 S6K levels. These results are consistent with 
previous reports that demonstrate activation of mTORC1 through disruption of the 
TSC1/2 complex, [23–25] and inhibition of mTORC1 through Raptor knockdown 
[26,27].  
 Genetic manipulation of mTORC1 activity has revealed a pivotal role of the 
kinase in lipid homeostasis [17,28]. mTORC1 activity is required for the activation of the 
transcription factor SREBP-1c, and constitutively active mTORC1 through loss of the 
TSC1/2 complex stimulates the expression of SREBP-1c targets and promotes 
lipogenesis [9,10,29]. Our model of constitutively active or inactive mTORC1 did not 
significantly affect SREBP-1 or FASN transcript levels, nor did it affect protein levels of 
FASN under hyperglycemic conditions. However, constitutive activation of mTORC1 led 
to a marked increase in DGAT1 and DGAT2 mRNA levels. We observed significant 
differences in cellular TG content in our models, despite the absence of an effect on 
lipogenic gene expression. Recently, a report demonstrated that TSC2-/- MEFs 
experienced stimulation of de novo lipogenesis that was dependent on SREBP-1 [29]. We 
did not measure de novo lipid synthesis in the present study; however, our study suggests 
that our model of hepatic mTORC1 hyperactivation does not increase lipogenesis in a 
SREBP1/FASN mediated manner, rather it increases TG synthesis through DGAT1 and 
DGAT2. DGAT1 catalyzes the incorporation of exogenous FFAs into TG, whereas 
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DGAT2 incorporates glycerol-3-phosphate and endogenously derived FFAs into TG 
[30,31]. These two enzymes operate sequentially with DGAT2 functioning upstream to 
catalyze the initial synthesis of DAG that becomes the substrate for DGAT1 [31].  
Glucose and high carbohydrate diets can upregulate the expression of DGAT1 and 
DGAT2, [32,33] however we did not observe an increase in DGAT1 or DGAT2 in our 
shScramble or shRaptor cells. This indicates that hyperactivation of mTORC1 induces 
the expression of DGAT1 and DGAT2 in a manner that is independent of glucose levels; 
however the exact mechanisms remain to be elucidated.  
 Constitutive activation of mTORC1 also led to a significant increase in two genes 
involved in lipid mobilization, APOB and MTP. MTP facilitates the lipidation of apoB 
from a cystosolic TG pool. This event is required for secretion of apoB-containing 
lipoproteins as it prevents proteasomal degradation of apoB. Our model of mTORC1 
hyperactivation increased the secretion of apoB and TG, presumably due to increased 
availability of cellular TG to MTP for lipidation of apoB. Conversely, the chronic 
inhibition of mTORC1 attenuated the mobilization of apoB-containing lipoproteins and 
TG. This is possibly a result of decreased cytosolic TG available to lipidate apoB, and the 
ensuing degradation of underlipidated apoB.  
 mTORC1 activity is stimulated by growth factors through the canonical insulin 
and Ras signaling pathways [5,29]. FBS contains a variety of growth factors, and serum 
withdrawal did not impact mTORC1 activity in TSC2-/- MEFs [29]. Our results 
corroborate earlier reports that suggest removal of FBS does not affect knockdown or 
mTORC1 activity in cell models of mTORC1 chronic hyperactivation or inhibition. We 
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also examined whether DMSO would affect secretion of apoB from our cells. In 
agreement with data reported by Borradalie et al. [34], treating our cells with DMSO 
(0.1% v/v) did not affect apoB secretion in shTSC2 cells, nor did it alter the apoB 
secretion trends observed between the three cell lines. These results indicate that our 
experimental conditions are valid for future studies.  
 Our model of mTORC1 constitutive activation is unique, in that it mimics the 
pathophysiological conditions (e.g., insulin resistance, obesity) in which 
hypertriglyceridemia is present. In a healthy cell, mTORC1 is activated postprandially 
via insulin and other nutrients. mTORC1 then phosphorylates p70 S6K, which targets 
IRS1 to inhibit insulin-dependent activation of mTORC1. When a cell is insulin resistant 
and in a state of nutrient excess the negative feedback on IRS1 is maintained, however 
mTORC1 signaling remains active likely through the action of overnutrition. The 
inhibition of IRS1 and Akt turns off the insulin-mediated suppression of hepatic 
lipoprotein secretion, while maintaining mTORC1-dependent de novo lipogenesis. The 
newly formed lipids are then used to lipidate apoB and are secreted from the hepatocyte 
as VLDL.  Suppressing TSC2 inhibits the GAP activity of the TSC1/2 complex, thus 
allowing the constitutive activation of mTORC1 signaling, independent of the insulin 
state of the cell. Our model demonstrates that chronic activation of mTORC1 leads to a 
significantly higher levels of lipogenic gene expression and TG synthesis, along with 
higher levels of secreted apoB and TG. Thus, we conclude that our model of 
constitutively active mTORC1 closely resembles the purported pathophysiology of 
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hypertriglyceridemia and is a useful tool to investigate the role of bioactive compounds in 
reversing aberrant mTORC1 signaling and its sequelae.  
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CHAPTER 3 
ATTENUATION OF mTORC1-DRIVEN 
SECRETION OF LIPOPROTEINS AND 
TRIACYLGLYCERIDES
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INTRODUCTION 
 
 In Chapter 2, we report that constitutively active mTORC1 induces expression of 
genes involved in lipogenesis (e.g., DGAT1, DGAT2) and lipid transport (e.g., APOB, 
MTP) with a concomitant increase in secretion of apoB and TG from hepatocellular 
carcinoma (HepG2) cells. These results suggest that mTORC1 plays a critical role in the 
development of hypertriglyceridemia, and that targeting the complex therapeutically 
would be a useful tool in correcting elevated TG in humans. However, kidney transplant 
patients treated with mTORC1-specific inhibitors experience dyslipidemia consisting of 
hypertriglyceridemia, hypercholesterolemia, and elevated plasma FFA [1,2]. This 
seemingly paradoxical scenario arises from a loss of mTORC1 negative feedback on 
insulin-mediated signaling, allowing Akt to promote lipogenesis through induction of 
SREBP-1c. Elevated de novo lipid synthesis will facilitate lipidation of apoB, allowing 
the lipoprotein to escape proteasomal degradation and be secreted from the hepatocyte as 
a component of VLDL. Thus, direct inhibition of mTORC1 is not a viable treatment 
strategy. An alternative therapeutic method involves the activation of catabolic pathways 
to counter-act mTORC1-driven anabolism. Fibrates (e.g., Fenofibrate) are a class of 
amphipathic carboxylic acids that are used as the first line drug therapy to treat 
hypertriglyceridemia. Fibrates impart their lipid lowering properties by activating 
peroxisome proliferator-activator receptor alpha (PPARα), that in turn promotes 
catabolism and lipoprotein clearance [3].  Though effective, these drugs are associated 
with several side effects including stomach upset, myopathy, and increased risk of 
gallstones [3]. These negative effects led us to explore the lipid lowering properties of 
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two short chain fatty acids (SCFA) that have been suggested to promote catabolism 
through PPARα.  
 (R)-α-Lipoic acid (LA) is a naturally occurring organosulfur compound and 
SCFA. LA is enzymatically derived from octanoic acid and serves as an essential 
cofactor of lipoamide containing enzymes of aerobic metabolism.  Recent reports have 
suggested that LA has TG-lowering properties and can increase whole body energy 
expenditure by activating catabolic pathways (e.g., β-oxidation) [4]. Specifically, dietary 
supplementation of LA induced the expression of PPARα target genes involved in 
medium- and long-chain fatty acyl metabolism in the liver of ZDF rats [5]. These 
observations led us to explore the therapeutic potential of LA in attenuating mTORC1-
driven hypertriglyceridemia.   
 4-Phenylbutyric acid (PBA) is an aromatic SCFA that is a chemical derivative of 
butyric acid, produced in the colon by fermentative bacteria. PBA is a well-described 
chemical chaperone used to alleviate endoplasmic reticulum (ER) stress by rescuing 
conformational abnormalities of proteins. However, there is mounting evidence that the 
SCFA can activate liver catabolic processes. For instance, PBA supplementation induced 
the expression of PPARα and genes involved in peroxisomal β-oxidation in livers of mice 
[6], and decreased hepatic protein levels of ACC, FAS, SREBP-1, and SCD-1 [7]. PBA 
supplementation also lowered serum triacylglycerides [8], ameliorated hepatic steatosis 
[7,9], and decreased body weights in rodents [6]. PBA treated TSC1-/- and TSC2-/- MEFs 
also experienced a reduction in phospho-p70 S6K levels suggesting that the chaperone 
may attenuate mTORC1 signaling [10]. These observations led us to investigate the 
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therapeutic potential of PBA in reversing mTORC1-mediated hypertriglyceridemia 
through the induction of catabolism.   
 
MATERIALS AND METHODS 
 
Reagents 
 We obtained 4-Phenyl butyric acid (PBA) from Acros Organics (#130380250); 
(R)-α-Lipoic acid from MAK Wood (#RALA1100134); and Dimethyl Sulfoxide 
(DMSO) from ATCC. LA was dissolved in DMSO to a stock concentration of 200 mM 
and diluted to a final concentration of 200 μM. PBA was dissolved in DMEM medium to 
a final concentration of 8 mM.  
 
Cell Culture 
 Previously validated stably transduced shScramble and shTSC2 HepG2 cells were 
maintained in low glucose (5.5 mM) Dulbecco’s Modified Eagle’s Medium (#11885-076; 
Life Technologies) supplemented with 10% fetal bovine serum (FBS) (#30-2020; ATCC) 
and antibiotics/antimycotics (#A5955; Sigma). Cells were maintained at 37oC in 5% CO2 
with medium renewal every 3-4 days. For experimental treatments, cells were washed 
twice with PBS, serum-starved overnight (~16-24 hrs), and treated as indicated in 
corresponding figure legends in serum-free DMEM (5.5 mM or 30 mM glucose). 
Cell lysis and Western blotting 
 Cells were washed twice in ice-cold phosphate-buffered saline (PBS) and 
solubilized in modified RIPA buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 
1 mM EGTA, 1% Na deoxycholate, 1% Igepal, 1 mM DTT) supplemented with Halt 
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protease and phosphatase inhibitors (Thermo Scientific). The cells were then scraped, 
vortexed for 1 minute, and then clarified by centrifugation for 10 min at 14,000 x g at 
4oC. Total protein concentration of clarified supernatants was determined using the Pierce 
BCA Assay (Thermo Scientific) and Bio-Tek µQuant plate reader. Samples were then 
adjusted to appropriate concentrations using ice-cold PBS and SDS loading buffer 
supplemented with 100 mM DTT, and denatured for 5 min at 95oC. Secreted proteins in 
conditioned media were prepared by adding Halt protease inhibitors (Thermo Scientific), 
vortexing, and centrifugation for 10 min at 14,000 x g at 4oC. The clarified media was 
then transferred to a fresh tube, vortexed briefly, and equal volumes denatured with SDS 
loading buffer supplemented with 100 mM DTT denatured for 5 min at 95oC, and 
subjected to Western blot analysis. Briefly, proteins were resolved by reducing SDS-
PAGE, transferred onto a nitrocellulose membrane (LI-COR), blocked for 1 hour at room 
temperature in Odyssey Blocking Buffer (LI-COR) in TBS, and probed overnight at 4oC 
with respective primary antibody. Antibodies against Raptor (#2280), TSC2 (#4308), p70 
S6K (#2708), phospho-p70 S6K (Thr389; #9234), AMPKα (#2603), phospo-AMPKα 
(Thr172; #2535) were purchased from Cell Signaling (Danvers, MA); ApoB (#71307) 
and ApoE (#7107) from Midland Bioproducts (Boone, IA); β-Actin (#A5441); IRDye 
secondary antibodies were purchased from LI-COR (Lincoln, NE). HRP-conjugated 
secondary antibodies against rabbit, mouse, and goat were purchased from R&D 
Systems, Cell Signaling, and Santa Cruz Biotechnology, respectively. Blots were 
visualized using either the LI-COR Odyssey scanner or enhanced chemiluminescence 
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(ECL) on the ProteinSimple imaging system. All band densitometry quantification was 
completed with the LI-COR Image Studio Lite software.  
Measurement of intracellular and secreted TG content 
 Lipids were extracted from stably transduced HepG2 cells and conditioned media 
(2 mL) using the chloroform/methanol method previously described with modifications 
[11]. TG were then quantified enzymatically using Triacylglyceride determination 
reagents (Sigma) and Bio-Tek µQuant plate reader. 
Statistical Analysis 
 Results are expressed as means ± SEM. Statistical significance was determined as 
denoted in figure legends using an unpaired two-tailed Student’s t test. Statistical tests 
were performed at the 5% significance level.   
 
RESULTS 
 
LA decreases cellular TG and secretion of lipoproteins and TG by attenuating 
mTORC1 signaling in an AMPK independent manner 
 To determine if LA supplementation would overcome mTORC1-driven 
overproduction of lipoproteins and TG, we treated stably transduced shScramble and 
shTSC2 HepG2 cells with 200 μM LA for 24 and 36 hrs in the presence of 5.5 mM and 
30 mM glucose (Fig. 3.1, A). LA (24 hrs) significantly decreased the phosphorylation of 
p70 S6K in shTSC2 cells, but had no effect on mTORC1 activity in shScramble cells 
(Fig. 3.1, B). Considering LA is purported to activate AMP-activated protein kinase 
(AMPK), which inhibits mTORC1 [12,13], we examined the phosphorylation of AMPKα 
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to determine if the suppression of mTORC1 activity stemmed from AMPK activation. 
We did not observe increased phospho-AMPKα in LA treated shTSC2 suggesting that 
the inhibitory effect of LA on hyperactive mTORC1 occurred in mechanism that is 
independent of AMPK (Fig. 3.1, C). We next sought to investigate the impact of LA (24 
hrs) supplementation on the secretion of apoB and apoE from shScramble and shTSC2 
cells under 5.5 mM and 30 mM glucose conditions. LA (24 hrs) significantly reduced 
secreted apoB (-26%) and apoE (-36%) from shTSC2 cells when cultured under 5.5 mM 
glucose (Fig. 3.1, E), but did not affect lipoprotein secretion from shScramble cells (Fig. 
3.1, D). LA (36 hrs) significantly lowered cellular TG (Fig. 3.1, G) and secreted TG (Fig 
3.1, I) from both shScramble and shTSC2 cells under 30 mM glucose conditions. This 
effect was not observed in cells cultured in 5.5 mM glucose (Fig. 3.1, F & Fig. 3.1, H). 
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Fig 3.1. LA attenuates hyperactive mTORC1 activity and decreases secretion of 
lipoproteins and TG. Phospho-p70 S6K was normalized to total p70 S6K, and phospho-
AMPKα to total AMPKα. Data represent mean ± SEM. (A) shScramble and shTSC2 
cells were treated with 200 µM LA for 24 hrs to examine mTORC1 activity and 
lipoprotein secretion or 36 hrs to examine intracellular and secreted TG content. (B) LA 
(24 hrs) attenuates hyperactive mTORC1 signaling, but does not affect mTORC1 activity 
in shScramble cells in 30 mM glucose (n = 4). (C) LA (24 hrs) does not activate AMPK 
in shTSC2 cells (n = 4). (D) LA (24 hrs) did not alter apoB or apoE secretion from 
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shScramble (n = 7). (E) LA (24 hrs) significantly decreased the secretion of apoB and 
apoE from shTSC2 cells under 5.5 mM and 30 mM glucose conditions (n = 7). LA (36 
hrs) supplementation did not alter (F) cellular TG or (H) secreted TG from shScramble or 
shTSC2 cells under 5.5 mM glucose (n = 6). Under 30 mM glucose conditions, LA (36 
hrs) significantly decreased (G) cellular TG and (I) secreted TG from both cell lines (n = 
6). Statistical significance was determined using Student’s t-test, *P < 0.05 vs. vehicle 
control. 
 
 
PBA decreases secretion of lipoproteins and TG without altering hyperactive 
mTORC1 signaling 
 Stably transduced shScramble and shTSC2 cells were treated with 8 mM PBA for 
6 hrs to determine if PBA would attenuate mTORC1-driven secretion of lipoproteins and 
TG (Fig. 3.2, A). PBA treatment did not attenuate hyperactive mTORC1 signaling in 
shTSC2 cells; however, the SCFA markedly decreased mTORC1 activity in shScramble 
cells (Fig. 3.2, B). Next, we sought to determine whether PBA treatment would alter 
lipoprotein and TG secretion from the two cell lines. PBA significantly decreased apoB 
and apoE secretion from both shScramble and shTSC2 cells without affecting mTORC1 
signaling (p-p70 S6K:p70 S6K) in shTSC2 cells (Fig. 3.2, C & F). Moreover, the 
decrease in lipoprotein secretion was similar between the two cell lines. PBA also 
significantly lowered the secretion of TG from shScramble and shTSC2 cells by 56% and 
26%, respectively.  
 We next examined the cellular TG content of PBA treated cells to determine if 
PBA would represses TG synthesis. PBA did not alter the cellular concentration of TG in 
shScramble cells (Fig. 3.2, D); however, PBA significantly increased cellular TG (+76%) 
in shTSC2 cells (Fig. 3.2, G). This effect had no negative consequences on cell 
morphology (Fig. 3.2, I). 
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Fig 3.2. PBA treatment decreases secretion of apolipoproteins and TG from cells 
with hyperactive mTORC1 signaling without altering mTORC1 activity. Phospho-
p70 S6K was normalized to total p70 S6K. Data represent mean ± SEM. (A) shScramble 
and shTSC2 cells were treated with 8 mM PBA for 6 hours and then analyzed for 
mTORC1 activity, apolipoprotein and TG secretion, and cellular TG content. (B) PBA 
treatment did not alter hyperactive mTORC1 signaling in shTSC2 cells, but significantly 
decreased mTORC1 activity in shScramble cells. PBA treated shScramble cells secreted 
less (C) apoB, apoE, and (E) TG. (D) PBA did not alter cellular TG content in 
shScramble cells. PBA treated shTSC2 cells secreted less (F) apoB, apoE, and (H) TG. 
(G) There was significantly more intracellular TG (+76%) in PBA treated shTSC2 cells. 
(I) Six hour PBA treatment did not alter cellular morphology of shScramble or shTSC2 
cells. Statistical significance was determined using Student’s t-test, *P < 0.05 vs. no PBA 
control, n = 3-4. 
 
DISCUSSION 
 
 Proper mTORC1 signaling is critical for many metabolic processes, especially in 
regards to anabolic metabolism. In states of overnutrition, insulin resistance, and obesity 
mTORC1 signaling becomes dysregulated and contributes to the development of 
hypertriglyceridemia. Pharmacological agents that directly target the mTORC1 complex 
are available; however, these drugs have negative side effects that include 
hypertriglyceridemia, hypercholesterolemia, and elevated plasma FFA [1]. This paradox 
has garnered interest in identifying potential bioactive agents that can counteract 
hyperactive mTORC1 through the induction of catabolism. The results presented in this 
study demonstrate that LA and PBA may be beneficial dietary aids in reversing 
mTORC1-driven secretion of lipoproteins and TG; however the SCFAs appear to impart 
their lipid lowering properties in distinct mechanisms.  
 AMPK senses intracellular energy status, promotes catabolic pathways, and 
inhibits mTORC1 activity [12,14].  LA has previously been shown to reduce mTORC1 
signaling in the skeletal muscle of high fat diet fed rats in an AMPK dependent manner 
62 
 
[13]. Our data show that LA suppresses hyperactive mTORC1 signaling in hepatocytes 
without activating AMPK. This is consistent with our previous studies that suggest that 
LA imparts its health-promoting properties independently of AMPK in the livers of ZDF 
rats [5,15,16]. To our knowledge, this is the first report of the inhibitory action of LA on 
hyperactive mTORC1 in hepatocytes. Previous data from our group also demonstrated 
that dietary supplementation of LA induces the expression of PPARα target genes (e.g., 
Cpt1β, Crat, Acot1, Acot2) while repressing lipogenic genes (e.g., Fas, Gpat1, Dgat2) in 
livers of ZDF rats [5]. We postulate that LA suppressed mTORC1 signaling by inducing 
catabolism possibly through the action of PPARα; however, more research is needed to 
fully define the molecular mechanisms. Additionally, our data suggest that LA represses 
lipoprotein secretion under abnormally elevated mTORC1 signaling (shTSC2 cells) 
without altering lipoprotein secretion at baseline mTORC1 activity (shScramble cells).  
We also reported that LA supplementation can decrease cellular TG and secreted TG in 
shScramble and shTSC2 cells when cultured under hyperglycemic conditions. The 
decrease in lipoprotein and TG from LA-treated shTSC2 cells is similar, if not superior, 
to the reductions achieved with the pharmacological lipid-lowering agents Gemfibrozil 
(fibrate) [17] and Simvastin (statin) [18] in HepG2 cells. 
 PBA has previously been shown to decrease mTORC1 signaling in TSC1-/- and 
TSC2-/- MEFs [10,19]. Our data show that PBA can significantly repress mTORC1 
signaling in control cells (shScramble), but not in shTSC2 HepG2 cells. Though 
mTORC1 signaling was unaffected by PBA in shTSC2 cells, we noted an abatement of 
lipoprotein and TG secretion that is consistent with in vivo studies [7,8]. For instance, 
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PBA (0.5 g/kg body weight; gavage) has been shown to suppress the secretion of 
apoB100 and lower serum TG content in ob/ob mice [8].  
 We observed a marked increase in intracellular TG content in PBA-treated 
shTSC2 cells. This effect was previously observed in the livers of PBA treated db/db 
mice, in which TG content increased despite elevated levels of phospho-ACC, a marker 
of decreased de novo lipogenesis [20]. db/db mice have upregulated hepatic mTORC1 
signaling that parallels our model and may explain the observed similarities between in 
vitro and in vivo models [21]. Taken together, our data suggest that PBA promotes the 
degradation of apolipoproteins without inhibiting hyperactive mTORC1 activity. 
Consequently, de novo lipogenesis proceeds unabated and leads to TG deposition in 
intracellular lipid droplets. It is important to note that PBA treatment was previously 
shown to ameliorate hepatic steatosis in high-fructose-fed rats and decrease intracellular 
TG in 30 mM glucose treated HepG2 cells [7,12]. mTORC1 activity was not reported in 
the aforementioned studies. Further investigation is needed to unveil the mechanisms by 
which PBA decreases TG secretion but increases TG deposition in hepatocytes in relation 
to mTORC1.  
 In summary, findings presented in this study show that LA and PBA can repress 
the secretion of apoB, apoE, and TG from HepG2 cells in the context of mTORC1 
hyperactivation. LA supplementation can attenuate hyperactive hepatic mTORC1 
signaling. LA and PBA are used clinically to treat a variety of diseased states, yet their 
lipid lowering properties have recently been recognized. Our findings suggest that the 
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two SCFAs may be beneficial bioactive compounds in the treatment of mTORC1-driven 
hypertriglyceridemia.  
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Chapter 4 
 
CONCLUSIONS 
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CONCLUSION 
 
 The effects of constitutively active mTORC1 on the secretion of apoB-containing 
lipoproteins and TG from human hepatocellular carcinoma cells was examined in this 
thesis. Our study demonstrates that hyperactive mTORC1 increases intracellular TG 
content, with a concomitant increase in apoB and TG secretion (Figure 4.1).  The 
observed increases in cellular and secreted TG are thought to result from TG synthesis, 
facilitated by hepatic DGAT1 and DGAT2. Subsequently, TG are used in the lipidation 
of apoB mediated by MTP, and secreted by hepatocytes as VLDL. By showing that 
constitutively active mTORC1 promotes the secretion of TG-rich apoB-containing 
lipoproteins, our studies provide new insight into the pathogenesis of 
hypertriglyceridemia.  
 Direct inhibition of mTORC1 is not a viable therapeutic strategy to treat 
mTORC1-driven hypertriglyceridemia as it increases TG synthesis and export. For 
example, patients treated with the mTORC1 inhibitor rapamycin develop 
hypertriglyceridemia, hypercholesterolemia, and elevated free fatty acids. An alternative 
approach is to stimulate catabolism to counteract mTORC1-driven anabolism. We found 
that two bioactive short chain fatty acids (SCFA) with purported catabolic properties, LA 
and PBA, can decrease the secretion of apoB-containing lipoproteins and TG in our 
model of mTORC1constitutive activation. However, the mechanism by which these two 
SCFAs impart their lipid lowering properties differ (Figure 4.1). Our data suggest that 
LA decreases the availability of cellular TG for apoB lipidation by repressing hepatic 
mTORC1 signaling. Since LA did not affect the secretion of apoB, we infer that LA led 
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to the secretion of poorly lipidated apoB particles. PBA, however, significantly repressed 
apoB and TG secretion, but did not influence mTORC1 signaling. Consequently, 
mTORC1-driven lipogenesis continued unabated, raising cellular TG synthesis. Over all, 
this work provides mechanistic insight into the lipid lowering properties of LA and PBA 
within the context of elevated mTORC1 signaling, and suggests that the two SCFAs have 
beneficial properties in the treatment of hypertriglyceridemia. 
  
 
Figure 4.1. Proposed lipid-lowering mechanisms of LA and PBA in a model of 
constitutively active mTORC1. (A) Hyperactive mTORC1 increases lipogenesis and 
intracellular TG that is utilized by MTP to lipidate apoB. Fully lipidated apoB and TG are 
then secreted as VLDL. (B) LA attenuates hyperactive mTORC1 signaling and 
lipogenesis, without affecting the secretion of apoB. Consequently, secreted apoB is 
poorly lipidated and less TG is present within VLDL. (C) PBA does not affect 
hyperactive mTORC1 signaling or lipogenesis, but represses secretion of apoB-
containing lipoproteins. Hindered lipid mobilization increases the TG content of the cell, 
stemming from increased deposition of TG in intracellular lipid droplets.  
 
